AstraZeneca's (AZN.US) star asthma drug Fasenra failed to reach the primary endpoint in the late-stage study for COPD treatment.

According to the Wise Finance APP, AstraZeneca (AZN.US) stated on Wednesday that its asthma drug Fasenra did not control the rate of acute exacerbations in a late-stage study of patients with chronic obstructive pulmonary disease (COPD, also known as "smoker's lung"). This setback poses a challenge to the company's efforts to combat this serious lung disease.